This HTML5 document contains 175 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://dx.doi.org/10.1177/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q50279616
rdf:type
wikibase:Item
schema:description
naučni članak სამეცნიერო სტატია artikull shkencor vetenskaplig artikel vědecký článek bài báo khoa học vitskapeleg artikkel article científic 2015年学术文章 2015년 논문 artikel ilmiah 2015年学术文章 artigo científico научни чланак 2015年の論文 artículu científicu مقالة علمية نشرت في 20 أبريل 2015 article scientific vitenskapelig artikkel 2015年学术文章 2015年學術文章 2015年学术文章 научная статья vedecký článok мақолаи илмӣ articolo scientifico artykuł naukowy wetenschappelijk artikel 2015年学术文章 επιστημονικό άρθρο научни чланак bilimsel makale article scientifique artículo científico publicado en 2015 2015年學術文章 наукова стаття, опублікована у квітні 2015 scientific article published on 20 April 2015 teaduslik artikkel מאמר מדעי 2015年学术文章 tudományos cikk artikulong pang-agham 2015年學術文章 scientific article published on 20 April 2015 videnskabelig artikel ২০ এপ্রিল ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articol științific tieteellinen artikkeli 2015 nî lūn-bûn บทความทางวิทยาศาสตร์ научна статия artigo científico 2015年學術文章 scienca artikolo artigo científico 2015年學術文章 scientific article published on 20 April 2015 wissenschaftlicher Artikel
p:P577
wds:Q50279616-31C02972-85F7-4BB6-82CE-02BF0FB5D8FC
wdt:P577
2015-04-20T00:00:00Z
p:P2860
wds:Q50279616-598F7C12-DE7C-4087-B1AB-0F6CACA06BE9 wds:Q50279616-6130C3DE-A61B-4B21-94A9-DDCD9AB8A0E6 wds:Q50279616-690F11A0-AD3D-4B80-B51D-7CC09D58C89F wds:Q50279616-4D7FC78B-376B-4128-9678-497419175A9F wds:Q50279616-4EB7522F-A841-4BB7-A779-2397FA530288 wds:Q50279616-8900702C-1FCA-4140-AC87-FFD975C09BA2 wds:Q50279616-8C403D71-52C7-4457-B4E9-2B1CE7C0FF1B wds:Q50279616-7886ABE0-790E-4184-916D-9165B303A4A2 wds:Q50279616-7B630212-A8BD-4D73-88BE-8330CA922883 wds:Q50279616-85F608DF-8772-4BA9-A5ED-DB2E636B3D59 wds:Q50279616-230A8F5F-F136-44E5-9A0F-2E9C6086A181 wds:Q50279616-2396E01F-E6E9-4024-9E11-4132A72334BB wds:Q50279616-211063A7-C779-49E6-9818-1C625AE22760 wds:Q50279616-211E3489-59AB-4DF6-9E68-52927446ABBB wds:Q50279616-377BAB15-79DC-49B7-8D17-176F35C4BCDB wds:Q50279616-38D1F045-367A-4D51-B8D9-8BA7C764D1D5 wds:Q50279616-2EE8983B-8166-473A-8011-D4B67BAB36F6 wds:Q50279616-FB924F61-15A0-4458-A1E1-481D830DC854 wds:Q50279616-AF7598D7-463C-44A2-B2CF-BBE04018DAD4 wds:Q50279616-8DC0F0C7-D9DA-45D8-A9F0-E6149C0A2B27 wds:Q50279616-95D83104-10B0-458D-9AE5-D6CD3494E343 wds:Q50279616-9D9D39A8-6CFF-43B6-A113-EDF088373F44 wds:Q50279616-E8C036FF-E366-480E-BCEA-33D2056E3CA5 wds:Q50279616-FA4CDB7F-29AA-403D-8316-D2A37AA867DD wds:Q50279616-C2F14F92-72C4-4212-A658-F6ECE4A102AD wds:Q50279616-C627F39A-A2E8-4AD5-AD9F-8B2823C02780 wds:Q50279616-E1ED83FD-125D-42CC-BFDA-CDA5398F97ED wds:Q50279616-021373F2-439A-4AAB-B702-923064B6244E wds:Q50279616-0479DE4F-6DEB-4844-95B8-3984BA885BB7 wds:Q50279616-05AC61EE-1C6A-4251-94BB-9E7DD91981D2 wds:Q50279616-17032F15-92C6-4D2F-88CF-234E94B7282E
wdt:P2860
wd:Q44928926 wd:Q46375283 wd:Q44398173 wd:Q28258641 wd:Q22242895 wd:Q44276262 wd:Q28304047 wd:Q28303050 wd:Q51553232 wd:Q24596908 wd:Q37088475 wd:Q36985650 wd:Q48382545 wd:Q30947051 wd:Q36047672 wd:Q37492808 wd:Q56687387 wd:Q34254289 wd:Q37811133 wd:Q37248137 wd:Q40058838 wd:Q50444955 wd:Q34616121 wd:Q34174388 wd:Q45336095 wd:Q57252735 wd:Q28205094 wd:Q34293267 wd:Q34279011 wd:Q38448455 wd:Q57483864
p:P2093
wds:Q50279616-AF8225BF-6F9E-465C-AB21-DA56A7F59AAD wds:Q50279616-BE72A6F3-2835-4342-BEA5-67B07419E302 wds:Q50279616-1BAC85C9-4D1A-4D41-BC92-3DA079C796D8 wds:Q50279616-491CDF60-3087-4165-9920-E315ECB06EFE wds:Q50279616-49297470-F59A-4352-8ED7-3FE51D05A4D6
wdt:P2093
Kenneth J Winters TRILOGY ACS investigators Keith Aa Fox Derek D Cyr Karen P Alexander
rdfs:label
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
skos:prefLabel
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes
schema:name
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
p:P50
wds:Q50279616-28391AF3-F6A3-4957-84F7-47C437D6809A wds:Q50279616-3149F9C8-54FD-4592-8BBB-6F05CE86E9C5 wds:Q50279616-27F35D22-36E7-4404-8784-AF1CD28D9B5E wds:Q50279616-6A815FD1-6336-4167-8ACC-2A08D9A12215 wds:Q50279616-5BE3BE79-6488-413D-981F-AE801A6AE949 wds:Q50279616-EBA6128A-27DC-4454-87B4-5F3460D2F2EB wds:Q50279616-F8E393BD-3DBB-4F22-A753-5490FE013B03 wds:Q50279616-A5B5B1E3-B62A-4038-8DB2-F9E4FF347CCF
wdt:P50
wd:Q60697402 wd:Q1587897 wd:Q64684757 wd:Q37390473 wd:Q39026591 wd:Q39026574 wd:Q72227369 wd:Q39730635
p:P1476
wds:Q50279616-199D7236-E1EE-4D03-8D7A-BD2832FAD496
wdt:P1476
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
p:P304
wds:Q50279616-FAF84CB0-DD6B-4847-89F7-0A4B1B26D21E
wdt:P304
231-242
p:P31
wds:Q50279616-42860994-F0AD-4720-9488-3D9C6C5F09B9
wdt:P31
wd:Q13442814
p:P921
wds:Q50279616-A119F2F9-CC55-44E1-AF4C-2B2DD4B2AFAA
wdt:P921
wd:Q266018
p:P698
wds:Q50279616-8DC027E4-8ACE-41D7-9332-F2949441FB7F
wdtn:P698
n10:25897147
wdt:P698
25897147
p:P1433
wds:Q50279616-2123D55E-C757-445F-80A6-DC0B91FE0091
wdt:P1433
wd:Q26853800
p:P433
wds:Q50279616-ACD51DE1-51FC-48D9-A886-478C8F8B043D
p:P478
wds:Q50279616-8885BC32-EBB7-4BCE-8CFA-75CDEC838767
wdt:P433
3
wdt:P478
5
p:P356
wds:Q50279616-5351F20F-F28D-4984-804B-8BCB295B5AAB
wdtn:P356
n6:2048872615581502
wdt:P356
10.1177/2048872615581502